Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Cash from Operations: 2015-2024

Historic Cash from Operations for UroGen Pharma (URGN) over the last 10 years, with Dec 2024 value amounting to -$96.8 million.

  • UroGen Pharma's Cash from Operations fell 52.80% to -$42.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$137.7 million, marking a year-over-year decrease of 43.26%. This contributed to the annual value of -$96.8 million for FY2024, which is 26.70% down from last year.
  • UroGen Pharma's Cash from Operations amounted to -$96.8 million in FY2024, which was down 26.70% from -$76.4 million recorded in FY2023.
  • In the past 5 years, UroGen Pharma's Cash from Operations ranged from a high of -$76.4 million in FY2023 and a low of -$105.9 million during FY2020.
  • Over the past 3 years, UroGen Pharma's median Cash from Operations value was -$87.6 million (recorded in 2022), while the average stood at -$86.9 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first slumped by 49.10% in 2020, then rose by 19.83% in 2021.
  • UroGen Pharma's Cash from Operations (Yearly) stood at -$105.9 million in 2020, then grew by 19.83% to -$84.9 million in 2021, then declined by 3.14% to -$87.6 million in 2022, then increased by 12.77% to -$76.4 million in 2023, then declined by 26.70% to -$96.8 million in 2024.